Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
| 2.01 | |
| 1.93 | |
| - | |
| 2.12 | |
| 1.91 | |
| 0.92-3.73 | |
| 692 M | |
| 361 M | |
| 3 641 K | |
| -0.17 | |
| 1.288 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Lexicon Pharmaceuticals, Inc. -Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments THE WOODLANDS, Texas, Oct. 16, 2024 ...
Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases Leverages Viatris' Unique Global Infrastructure and Expertise Includes Opportunities to Leverage the Potential of Sotag...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
